Fiscal 2022 targets of ¥710 billion in revenue and ¥37 billion in operating profit
First written in FY2021. . Latest entry: FY2022.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- FY2022Full-year results for the target fiscal year disclosedAnnual report
「Revenue was ¥625.477 billion, up 3.8% year on year, an increase of ¥22.627 billion. The main factors included business expansion resulting from the opening of 112 new stores, comprising 28 in Kanto, 31 in Chubu, 20 in Hokuriku and 33 in Kansai, as well as an increase in the number of stores providing dispensing services, which led to a 16.1% increase in prescriptions filled and higher dispensing revenue.」
As full-year results against the previous fiscal 2022 targets, the company disclosed revenue of ¥625.477 billion and operating profit of ¥32.137 billion. - FY2022-Q3Cumulative results for the first 3 quarters disclosedAnnual report
「Revenue was ¥466.528 billion, up 4.5% year on year, an increase of ¥20.244 billion. Operating profit was ¥23.281 billion, down 8.9%, a decrease of ¥2.287 billion.」
The company disclosed cumulative revenue of ¥466.528 billion and operating profit of ¥23.281 billion for the first 3 quarters against the fiscal 2022 targets. - FY2021First statedAnnual report
「The Group launched a medium-term management plan covering the 3 years from fiscal 2020 to fiscal 2022, with targets for fiscal 2022 of revenue of ¥710.0 billion and operating profit of ¥37.0 billion, representing an operating margin of 5.2%.」
The company records, for the first time as a standalone theme, the medium-term targets for revenue, operating profit and operating margin through fiscal 2022. For the first year, the fiscal year ended February 2021, it states that revenue was ¥602.5 billion and operating profit was ¥33.7 billion, versus targets of ¥600.0 billion and ¥30.0 billion, respectively, and that the first-year targets were achieved.